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Tumor necrosis factor (TNF) receptor associated factor-2 (TRAF2) knockout (KO) cells
were generated to investigate the role of TRAF2 in signaling by TNFR1 and the CD95-type
death receptors (DRs) TRAILR1/2 and CD95. To prevent negative selection effects arising
from the increased cell death sensitivity of TRAF2-deficient cells, cell lines were used
for the generation of the TRAF2 KO variants that were protected from DR-induced
apoptosis downstream of caspase-8 activation. As already described in the literature,
TRAF2 KO cells displayed enhanced constitutive alternative NFκB signaling and reduced
TNFR1-induced activation of the classical NFκB pathway. There was furthermore a
significant but only partial reduction in CD95-type DR-induced upregulation of the
proinflammatory NFκB-regulated cytokine interleukin-8 (IL8), which could be reversed
by reexpression of TRAF2. In contrast, expression of the TRAF2-related TRAF1 protein
failed to functionally restore TRAF2 deficiency. TRAF2 deficiency resulted furthermore
in enhanced procaspase-8 processing by DRs, but this surprisingly came along with a
reduction in net caspase-8 activity. In sum, our data argue for (i) a non-obligate promoting
function of TRAF2 in proinflammatory DR signaling and (ii) a yet unrecognized stabilizing
effect of TRAF2 on caspase-8 activity.
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INTRODUCTION
The death domain (DD)-containing receptors (DRs) of the tumor necrosis factor (TNF) receptor
superfamily (TNFRSF) can be subdivided into three groups according to how DD-containing
signaling proteins and caspase-8 are used to induce apoptosis (1). The receptors of the CD95-type
DR group (CD95) (Apo1, Fas), TNF-related apoptosis inducing ligand (TRAIL) receptor-1
(TRAILR1, DR4), and TRAILR2 (DR5) recruit procaspase-8 directly in the receptor signaling
complex by means of the DD-containing adapter protein Fas-associated death domain (FADD). In
contrast, the receptors of the TNFR1-type DR group (TNFR1, DR3) activate the FADD–caspase-8
dyad indirectly in cytosolic protein complexes. The receptors of the third group of DRs (p75NGFR,
EDAR, DR6) induce cell death under poorly defined circumstances by heterogeneous mechanisms
without obvious involvement of FADD and caspase-8. The CD95- and TNFR1-type DRs
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and DR6 also have the ability to trigger necroptotic cell
death via the receptor-interacting protein serine/threonine
kinase-1 (RIPK1)–RIPK3 mixed lineage kinase domain-like
(MLKL) pathway (2, 3). There are again clearly distinguishable
differences in the molecular mechanisms involved. While FADD
is essentially required for CD95-type DR-induced necroptosis,
TNFR1-induced necroptosis is even enhanced in the absence
of FADD (4, 5). The importance of FADD for DR6-induced
necroptosis has not been investigated, yet.
DRs of the CD95 and TNFR1 type are not only able to
induce cell death but can also trigger proinflammatory signaling
pathways leading to the activation of transcriptions factors
of the nuclear factor of kappaB (NFκB) family and mitogen-
activated protein (MAP) kinases (MAPKs) (1). Again, FADD
and caspase-8 are of differential relevance. CD95-type DRs
require FADD and caspase-8 for proinflammatory signaling
while both molecules are dispensable for proinflammatory
signaling by TNFR1-type DRs (1). RIPK1 and the DD-containing
adapter protein TNF receptor associated death domain protein
(TRADD), however, are crucially involved in TNFR1- and CD95-
type DR-induced NFκB signaling. The redundant role of TRADD
and RIPK1 in DR-induced classical NFκB signaling points to
a crucial role of the adapter protein TRAF2 (6–9). TRAF2
not only directly binds to short peptide motifs within the
cytoplasmic tail of receptors of the TRAF-interacting subgroup
of the TNFRSF but also interacts with TRADD and RIPK1
(10). In the context of signal transduction of TRAF-interacting
receptors, TRAF2 and the TRAF2-interacting E3 ligases cellular
inhibitor of apoptosis-1 (cIAP1) and cIAP2 have been strongly
implicated in activation of the classical NFκB pathway and the
JNK MAPK pathway (10, 11). There is furthermore manifold
evidence that TRAF2 in conjunction with the cIAPs promotes
proinflammatory signaling and limits apoptotic as well as
necroptotic activity of TNFR1-type DRs. TRAF2 has also an
anti-necroptotic function in CD95-type DR-induced necroptosis
(12, 13). The role of TRAF2 in proinflammatory signaling by
CD95-type DRs, however, has been poorly addressed so far. In
murine embryonal fibroblasts, TRAF2 was found to be required
for JNK signaling but was dispensable for NFκB activation
(14–17). In murine A20 cells, however, TRAF2 deficiency
resulted in inhibition of TRAIL-induced rapid NFκB signaling,
while it was dispensable at a later stage. Noteworthy, the
TRAF2-independent late mode of NFκB activation described
by Zhang et al. required caspase activation and MEKK1 (18).
It has been shown that MEKK1 is cleaved during apoptosis
by caspases with the release of a signaling stimulating kinase
active fragment (19, 20). Thus, the late mode of NFκB activation
presumably represents an apoptosis-associated event without
major relevance for CD95-type proinflammatory DR signaling
in resistant cells.
Abbreviations: cIAP1/2, cellular inhibitor of apoptosis-1/2; DR, death
receptor; ELISA, enzyme-linked immunosorbent assay; FC, flow cytometry;
IL8, interleukin-8; NFκB, nuclear factor kappaB; RIPK1, receptor-interacting
serine/threonine kinase 1; TNF, tumor necrosis factor; TNFR1/2, TNF receptor-
1/2; TRAF1/2, TNF receptor associated factor-1/2; TRAIL, TNF-related apoptosis
inducing ligand; TRAILR1/2, TRAIL receptor-1/2.
Here, we knocked out TRAF2 in HCT116-PI3Kmut and
HT1080-Bcl2-TNFR2 cells, which are resistant against DR-
induced apoptosis downstream of procaspase-8 processing due
to inhibition of Bax/Bak-mediated mitochondrial amplification
of the apoptotic caspase-8 activity (16, 21, 22). TRAF2-
deficient cells remained DR resistant but displayed reduced
proinflammatory DR signaling and an unexpected stabilizing
effect of TRAF2 on mature caspase-8.
RESULTS
TRAIL-Induced Activation of the Classical
NFκB Pathway in HCT116 Cells Does Not
Require Caspase-8 Activity
To investigate the relevance of TRAF2 in proinflammatory
DR signaling, we knocked out its expression in HCT116-
PI3Kmut cells, which express only a mutated active allele of
the PIK3CA oncogene causing constitutive degradation of Bax
(16, 23). The apoptosis-resistant variant was used for two reasons.
First, initially, we failed in apoptosis-competent cell lines to
obtain TRAF2 knockout (KO) cells with an otherwise well
working CRISPR/Cas9 protocol pointing to negative selection of
TRAF2 KO cells. Second, since deficiency of TRAF2 typically
sensitizes cells for DR-induced apoptosis and as the latter
in turn inhibits proinflammatory signaling, TRAF2-deficient
apoptosis-resistant cells promise easier dissection of direct
effects of TRAF2 deficiency from indirect effects resulting
from enhanced cell death sensitivity. In accordance with our
previous data (22), HCT116-PI3Kmut cells were largely resistant
against TRAIL-induced cell death, even in the presence of
CHX as an apoptosis sensitizer, while an HCT116 variant
harboring a PIK3CA wild-type allele was strongly TRAIL-
sensitive (Figure 1A). In accordance with the fact that DR-
resistance of HCT116-PI3Kmut cells is due to depletion
of Bax, which acts downstream of DR-associated caspase-8
activation, processing of caspase-8 was comparable between
HCT116-PI3Kmut and HCT116-PI3Kwt cells (Figure S1A). We
furthermore confirmed that TRAIL induces phosphorylation
of IκBα and production of the NFκB target interleukin-8
(IL8) in the HCT116-PI3Kmut variant (22) (Figures 1B,C).
TRAIL-induced IκBα phosphorylation slowly developed over
1–4 h to reach a plateau lasting several hours (Figure 1B).
In view of the controversial reports on the relevance of the
enzymatic activity of caspase-8 for CD95-type DR-induced
activation of the classical NFκB pathway (1), we analyzed
the impact of the pan-caspase inhibitor z-VAD-fmk (ZVAD).
While ZVAD completely prevented TRAIL-induced apoptosis in
the sensitive HCT116-PI3Kwt variant, it showed no significant
effect on TRAIL-induced IκBα phosphorylation in the HCT116-
PI3Kmut variant and even enhanced TRAIL-induced IL8
production (Figures 2A,B). In contrast, processing of caspase-
8 and processing of the caspase-8 substrate Cyld (24) were
fully inhibited by ZVAD (Figure 2B). Similar to ZVAD, the
specific caspase-8 inhibitor z-IETD-fmk (zIETD) prevented
caspase-8 processing but showed no inhibitory effect on IκBα
phosphorylation (Figure 2B). Again, there was also somewhat
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enhanced TRAIL-induced IL8 production in the HCT116-
PI3Kmut cells (Figure S1B). In sum, these data indicate that
TRAIL signals classical NFκB activation in HCT116 cells by a
caspase-8 activity-independent mode.
TRAF2 Deficiency Does Not Break Death
Receptor Resistance of HCT116-PI3Kmut
Cells but Attenuates Proinflammatory
Signaling
A TRAF2 KO variant of the HCT116-PI3Kmut cell line was
obtained using a CRISPR/Cas9 standard protocol (Figure 3A).
In accordance with the crucial role of TRAF2 in the suppression
of the alternative NFκB pathway, HCT116-PI3Kmut-TRAF2KO
cells showed constitutively enhanced p100 processing, which
was not further stimulable by established triggers of the
alternative NFκB pathway such as TWEAK and LTαβ2
(Figure 3B). Evaluation of TNF-induced phosphorylation
and degradation of IκBα and upregulation of IL8 revealed
furthermore a non-obligate contribution of TRAF2 to
TNF-induced proinflammatory signaling (Figures 3C,D).
In particular, despite the broadly documented survival activity
of TRAF2 in DR signaling, TRAF2 deficiency had no significant
effect on resistance of HCT116-PI3Kmut-TRAF2KO cells
against TRAIL- and TNF-induced cell death (Figure 3E).
TRAF2 deficiency also resulted in attenuated (∼50% reduction)
TRAIL-induced production of the NFκB target IL8. Due to
the only partial effect of TRAF2 deficiency on DR-induced
IL8 production, we confirmed the specificity of the effect by
reintroduction of TRAF2. Indeed, HCT116-PI3Kmut-TRAF2KO
transfectants stably expressing TRAF2 (HCT116-PI3Kmut-
TRAF2re) displayed restored IL8 responsiveness (Figures 4A,B).
TRAF2 forms heterotrimeric complexes with the closely related
TRAF1 protein (25). Moreover, TRAF2–TRAF1 heterotrimers
have been found to be superior to TRAF2 homotrimers with
respect to binding of cIAP1, which crucially contributes to the
activation of the classical NFκB pathway by members of the
TNFRSF (25). To evaluate whether TRAF1 enhances TRAIL-
induced IL8 production and/or substitutes for TRAF2 in this
process, we stably expressed TRAF1 in HCT116-PI3Kmut and
HCT116-PI3Kmut-TRAF2KO cells (HCT116-PI3Kmut-TRAF1;
HCT116-PI3Kmut-TRAF1-TRAF2KO; Figure 4C). Ectopic
TRAF1 expression showed no significant effect on TRAIL-
induced IL8 production irrespective of the presence of TRAF2
(Figure 4D). Noteworthy, there was enhanced TNF-induced
procaspase-8 processing in the absence of TRAF2 (Figures 4E,F),
which was fully rescued in the TRAF2-reconstituted cells
(Figure 4F). TRAF1 expression levels furthermore dropped
down after TNF treatment in the HCT116-PI3Kmut-TRAF1 but
not in HCT116-PI3Kmut-TRAF1-TRAF2KO cells (Figure 4E).
The latter might reflect the fact that TRAF1 is a substrate of
caspase-8 (26, 27). Indeed, using another TRAF1 antibody, we
observed significant cleavage of TRAF1 in TRAIL-stimulated
HCT116-PI3Kmut-TRAF1 cells (Figure 4G).
Similar IL8 induction results as observed with TRAIL
were furthermore obtained upon stimulation of CD95. Again,
IL8 induction was significantly reduced in HCT116-PI3Kmut-
TRAF2KO cells and restored to normal levels in the cell variant
with reconstituted TRAF2 expression without a significant
impact of TRAF1 expression (Figure 4H). To verify the relevance
of TRAF2 for CD95-type DR-induced IL8 production in an
independent cellular system, we deleted TRAF2 expression
in apoptosis-resistant HT1080-Bcl2-TNFR2 cells (Figure 5A).
Again, as expected, there was constitutive p100 processing to
p52 (Figure 5A). Moreover, there was again significantly reduced
IL8 upregulation by the death ligands TNF, Fc-CD95L, and
TRAIL (Figure 5B).
TRAF2 Deficiency Enhanced DR-Induced
Caspase-8 Processing
As shown above in Figures 4E,G, TRAIL-induced TRAF1
cleavage was more efficient in the presence than in the absence
of TRAF2. This was a bit surprising in view of the frequently
reported anti-apoptotic activity of TRAF2 and a previous
report describing TRAF2-dependent K48 ubiquitination of active
caspase-8 by cullin-3 resulting in proteasomal degradation of
active caspase-8 and an attenuated apoptosis response (9). On the
other side, it appears possible that in the special case of TRAF1,
its interaction with TRAF2 is required to make it available as
a substrate for caspase-8. FLIP proteins are presumably the
most potent regulators of procaspase-8 processing and interact
not only with caspase-8 but also with TRAF2 and TRAF1 (28,
29) Moreover, the long isoform of FLIP (FLIPL) can promote
the initial processing step of procaspase-8 processing (30, 31),
and murine embryonal fibroblasts of TRAF2 KO mice revealed
lower FLIP expression due to enhanced FLIP degradation (32).
Last but not least, expression of FLIP proteins is controlled,
among others, by the classical NFκB pathway (33, 34). In view
of the potential complex interplay of FLIP proteins, caspase-8,
TRAF2, and NFκB signaling, we evaluated expression of FLIP
proteins in HCT116-PI3Kmut andHCT116-PI3Kmut-TRAF2KO
cells. While FLIPL was readily detectable by Western blotting,
the short isoform FLIPS was not or only poorly expressed
(Figure 6A). It turned out that neither TNF (Figure 6A) nor
TRAIL (Figure S2A) upregulated FLIP expression in the parental
HCT116-PI3Kmut cells and there was also no obvious effect of
TRAF2 deficiency on FLIP expression. There was furthermore
no major difference in the recruitment of FLIP proteins to
the TRAIL death receptors in the HCT116-PI3Kmut-TRAF2KO
cells (Figure S2B). This suggests that the enhanced DR-induced
processing of procaspase-8 in TRAF2-deficient cells is not due
to a change in the expression of FLIP proteins. Moreover, in
accordance with earlier reports [e.g., (21, 35, 36)], we found
that expression of FLIPL, which promotes initial processing of
procaspase-8, as well as expression of FLIPS, which completely
prevents procaspase-8 processing, interfered with TRAIL- and
CD95L-induced IL8 production (Figure S2C). Noteworthy,
TNF-induced IL8 production remained unaffected by FLIPL/S
expression (Figure S2C). Since expression of FLIP proteins only
inhibited TRAIL- and CD95L-induced IL8 production and as
the two FLIP variants have opposing effects on procaspase-8
processing, it appears unlikely that the general effects of TRAF2
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FIGURE 1 | HCT116-PI3Kmut cells are largely protected from DR-induced apoptosis. (A) HCT116 cells carrying a single PI3K mut or wt allele were challenged
overnight with the indicated concentrations of TRAIL in the absence or presence of 2.5µg/ml CHX and analyzed for cellular viability. (B) Western blot evaluation of
phosphorylation and degradation of IκBα in HCT116-PI3Kmut cells stimulated with 100 ng/ml TRAIL. (C) Upregulation of IL8 production in HCT116-PI3Kmut cells
stimulated overnight with the indicated concentrations of TRAIL.
on DR-induced IL8 production and caspase-8 processing are due
to deregulated FLIP activity in TRAF2 KO cells.
In the following, we directly analyzed procaspase-8 processing
and caspase-8 activity in TRAF2 KO cells. Indeed, as expected
for an antiapoptotic function of TRAF2, there was also enhanced
procaspase-8 processing in TNF-stimulated HCT116-PI3Kmut-
TRAF2KO cells (Figure 6B). Interestingly, however, death-
ligand-induced caspase-8 activity, measured using the FLICA
method, was reduced in the TRAF2 KO cells (Figures 6C,D).
In line with the reduced caspase-8 activity, there was reduced
processing of the caspase-8 substrate Cyld in TRAF2-deficient
HCT116-PI3Kmut cells (Figure 6A). In accordance with the fact
that TRAF2 deficiency has no major effect on the viability of
DR-stimulated HCT116-PI3Kmut cells (Figure 2B), there was no
increase in propidium iodide staining, which was performed in
parallel with the detection of caspase-8 activity (Figure 6C).
The SMAC Mimetic BV6 Showed No Major
Effect on DR-Induced Proinflammatory
Signaling but Accelerated Procaspase-8
Processing
TRAF2 fulfills its functions in TNFRSF receptor signaling not
least by acting as an adapter to recruit cIAP1 and/or cIAP2.
We therefore tested whether treatment of HCT116-PI3Kmut
cells with the SMAC mimetic BV6, which triggers proteasomal
degradation of cIAP1 and cIAP2 (37), elicits effects similar
to TRAF2 deficiency. Expression of cIAP1 was comparable
between HCT116-PI3Kmut and HCT116-PI3Kmut-TRAF2KO
cells (Figure S3), and cIAP2 was practically not detectable.
Treatment with BV6 resulted in a strong reduction of cIAP1
expression in both cell variants. In good accordance with
the well-established fact that TRAF2 in concert with cIAP1
and cIAP2 inhibits NIK accumulation and NIK-promoted
processing of p100 to p52, BV6 stimulated the latter in
HCT116-PI3Kmut but not in HCT116-PI3Kmut-TRAF2KO
cells (Figure S3). Instead, there was constitutively enhanced
p100 to p52 processing in the HCT116-PI3Kmut-TRAF2KO
cells to an extent similar to those induced by BV6 in the
parental cell variant. Although there was enhanced steady-
state phosphorylation of IκBα phosphorylation in BV6-treated
HCT116-PI3Kmut cells, the dose response of TNF-induced
IκBα degradation remained largely unaffected (Figure 7A). BV6
treatment showed furthermore no effect on TNF-, TRAIL-,
and CD95L-induced IL8 production in HCT116-PI3Kmut cells
(Figure 7B). With exception of a minor effect on TNF-induced
IL8 production, there was also no effect of BV6 on DR-
induced IL8 induction in the HCT116-PI3Kmut-TRAF2KO cells.
BV6, however, improved TNF-induced caspase-8 processing in
a TRAF2-dependent manner; thus, it enhanced procaspase-8
processing in the HCT116-PI3Kmut cells but not in the TRAF2
KO variant derived thereof (Figure 7C).
DISCUSSION
Twenty-five years ago, TRAF2 and the TRAF2-interacting E3
ligases cIAP1 and cIAP2 have been identified as components
of the TNFR2 signaling complex (38, 39). Afterwards, within
a few years, it became evident that TRAF2 (and the cIAPs)
recruits directly or indirectly to most, if not all, transmembrane
receptors of the TNFRSF. In the context of signaling by receptors
of the TNFRSF, TRAF2 has been implicated in the activation
of classical NFκB pathways and signaling pathways, resulting
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FIGURE 2 | Proinflammatory TRAIL signaling does not require caspase activity in HCT116 cells. (A) Apoptosis-sensitive HCT116-PI3Kwt cells (left panel) and
apoptosis-resistant HCT116-PI3Kmut cells (right panel) were challenged as indicated with TRAIL and zVAD. The next day, IL8 production and cellular viability were
determined. (B) HCT116-PI3Kmut cells were stimulated with TRAIL in the presence of zVAD or zIETD for 6 h and were analyzed by Western blotting.
in the activation of MAP kinase cascades. Noteworthy, TRAF2,
in concert with the cIAPs and TRAF3, triggers the constitutive
proteasomal degradation of the MAP3K NIK, the key activator
of the alternative NFκB pathway, and thus suppresses the activity
of this signaling pathway (10, 11). Recruitment of TRAF2 to
receptors of the TNFRSF can deplete the cytosolic pool of TRAF2
molecules by translocation to the plasmamembrane and can thus
result in activation of the alternative NFκB pathway. Early on,
it became evident that TRAF2 also protects cells from TNFR1-
induced cell death. Initially, the protective activity of TRAF2 has
been attributed to its role in activation of the classical NFκB
pathway, but there is growing evidence that it also acts in an
NFκB-independent manner by interfering with the cytotoxic
activity of caspase-8 and/or RIPK1. Recent studies also point
to an anti-necroptotic role of TRAF2 in signaling by DRs of
the CD95 type (CD95, TRAILR1, TRAILR2), but the functions
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FIGURE 3 | TRAF2-deficient HCT116-PI3Kmut cells remain DR resistant. (A) HCT116-PI3Kmut and HCT116-PI3Kmut-TRAF2KO cells were analyzed by Western
blotting. (B) Cells were stimulated with 200 ng/ml of TNF, LTαβ2, or TWEAK or remained untreated. The next day, cells were again analyzed by Western blotting. (C,D)
Cells were stimulated overnight (C) or for 5min (D) with increasing concentrations of TNF. IL8 production (C) and phosphorylation and degradation of IκBα (D) were
analyzed as hallmarks of proinflammatory signaling by ELISA and Western blotting, respectively. (E) Cells were challenged overnight with TRAIL or TNF or a cytotoxic
cocktail containing 200 ng/ml TNF, 200 ng/ml Fc-CD95L, 200 ng/ml TWEAK, 5µg/ml CHX, 1µg/ml Puromycin, and 0.02% sodium azide and were analyzed for
viability by microscopic inspection (left panels) or crystal violet staining (right panels).
of TRAF2 in signal transduction of these death receptors
have been poorly addressed so far. We generated TRAF2 KO
variants of HCT116-PI3Kmut and HT1080-Bcl2-TNFR2 cells.
TRAF2 deficiency showed no major effect on the death receptor
resistance of HCT116-PI3Kmut cells. This is in good accordance
with the mode of protection in these cells. TRAF2 protects
from apoptosis at the level of caspase-8 activation and can thus
not bypass the anti-apoptotic effect of the downstream placed
Bax deficiency observed in HCT116-PI3Kmut cells. Nevertheless,
TRAF2 deficiency and cIAP1 depletion with the SMAC mimetic
BV6 come along with enhanced DR-induced processing of
procaspase-8 (Figures 6A, 7C). In accordance with the idea
that TRAF2 acts in concert with cIAP1 in this scenario, the
enhancing effect of BV6 treatment on TNF-induced procaspase-
8 processing was abrogated in TRAF2 KO cells (Figure 7C).
Surprisingly, enhanced DR-induced procaspase-8 processing in
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FIGURE 4 | Death receptor-induced IL8 production is attenuated by TRAF2 deficiency and is not restored by TRAF1 expression. (A) HCT116-PI3Kmut,
HCT116-PI3Kmut-TRAF2KO, and HCT116-PI3Kmut-TRAF2re cells were analyzed by Western blotting. (B) Cells were stimulated overnight with 200 ng/ml TRAIL and
IL8 production was assayed by ELISA. Shown are results from five independent experiments. (C) HCT116-PI3Kmut and HCT116-PI3Kmut-TRAF2KO cells along with
stable TRAF1 transfectants of these variants were analyzed by Western blotting. (D) Cells were analyzed as in “B.” Results are derived from six independent
experiments. (E,F) Cells were treated with increasing concentrations of TNF for 6 h in the presence of CHX (2.5µg/ml) and subjected to Western blot analysis.
(G) CHX-treated cells were stimulated with 200 ng/ml TRAIL for the indicated times and subjected to Western blot evaluation. (H) The indicated HCT116-PI3Kmut
variants were stimulated overnight with 200 ng/ml Fc-CD95L and IL8 production was again determined by ELISA. Shown are results from 10 independent
experiments. ***p < 0.001; **p < 0.01; n.s., not significant.
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FIGURE 5 | DR-induced IL8 production in TRAF2-deficient HT1080-Bcl2-TNFR2 cells. (A) HT1080-Bcl2-TNFR2 and HT1080-Bcl2-TNFR2-TRAF2KO cells were
analyzed by Western blotting. (B) Cells were stimulated overnight with 200 ng/ml Fc-CD95L, 2 ng/ml TNF, or 200 ng/ml TRAIL and IL8 production was determined by
ELISA. Shown are results from three to five independent experiments. ***p < 0.001; **p < 0.01; *p < 0.05; n.s., not significant.
TRAF2 KO cells did not correlate to an increase in net caspase-
8 activity. Indeed, there was even a reduction in caspase-
8 activity (Figures 6C,D). This might reflect varying specific
activities of the different species of enzymatically active caspase-
8 (CD95-type DR-bound caspase-8 homodimers, CD95-type
DR-bound caspase-8/FLIPL heterodimers, different cytosolic
caspase-8 containing complexes etc.) that exist in DR-stimulated
cells. This issue must be clarified in future studies. DRs do
not trigger necroptosis in HCT116 or HT1080 cells; the anti-
necroptotic activity of TRAF2 could therefore not be evaluated
in the TRAF2-deficient cells used in this study.
We found furthermore a significant and strong reduction
in TNF-induced degradation of IκBα in HCT116-PI3Kmut-
TRAF2KO cells (Figure 3D). This correlated with an only slight
reduction in TNF-induced upregulation of the NFκB-regulated
cytokine IL8 (Figure 3C). The inhibitory effect of TRAF2
deficiency on TNF-induced IL8 production appeared, however,
less pronounced at the level of IκBα degradation. This could
due to the fact that other TNFR1-induced pathways such as the
JNK or p35 pathway contribute to IL8 upregulation, but this
appears unlikely as NFκB signaling has practically an obligate
function in TNFR1-induced IL8 production. The relatively weak
effect of TRAF2 deficiency on TNF-induced IL8 production
could also be related to the non-linear and timely complex
relationship between IκBα degradation, resynthesis of IκBα,
nuclear NFκB activity, and IL8 mRNA synthesis. Thus, the
observed reduction in IκBα degradation might be compensated
for by diminished and delayed resynthesis of IκBα and a
weaker but sustained pathway activity resulting in an only
minor inhibitory effect on IL8 production. Indeed, an only
partial inhibitory effect of TRAF2 deficiency on TNF-induced
NFκB signaling has also been observed in TRAF2-deficient
embryonal fibroblasts (6). TRAIL induced IκBα phosphorylation
with rather slow kinetics, reaching a plateau after 2–4 h,
which lasts for several hours with a hardly detectable effect
on net expression levels of IκBα (Figure 1B). Nevertheless,
TRAIL-induced IL8 production was in the same range as
in the case of TNF (Figures 3C, 4B). TRAIL- and CD95L-
induced IL8 production was significantly reduced in TRAF2-
deficient cells as well (Figures 4B,D,H, 5B). Although TNF-
induced IL8 production appeared a bit less affected by TRAF2
deficiency than TRAIL- and CD95L-induced IL8 production
(27 vs. 49% and 45%), this did not result in a significant
difference (Figure S4). Noteworthy, although BV6 enhanced
TRAIL- and TNF-induced procaspase-8 processing, it had no
(TRAIL, CD95L) or only a very minor (TNF in TRAF2 KO
cells) effect on IL8 production (Figure 7B). This suggests that
reduced DR-induced IL8 production and accelerated caspase-8
processing in TRAF2 KO cells reflect at least two partly different
aspects of TRAF2 function in DR signaling. We observed
no consistent significant effect of TRAF2 deficiency on net
IκBα levels and IκBα phosphorylation in TRAIL- and CD95L-
treated cells (data not shown), although there was regularly
significantly reduced IL8 production. This could again reflect
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FIGURE 6 | TRAF2 deficiency has no major effect on FLIP expression of
HCT116-PI3Kmut cells but enhances TNF-induced procaspase-8 processing.
(A,B) HCT116-PI3Kmut cells (–) and its TRAF2-deficient variant (TRAF2-KO)
were challenged with TNF for 6 h in the presence of 2.5µg/ml CHX. Total cell
lysates were analyzed by Western blotting with respect to the indicated protein
species. (C) Cells were stimulated with 100 ng/ml TNF, TRAIL, and Fc-CD95L
again in the presence of 2.5µg/ml CHX, and caspase-8 activity was analyzed
using the fluorochrome-labeled inhibitor of caspases assay (FLICA) method
with FAM-IETD-FMK for caspase-8 detection. (D) Independent experiments
were performed as described in “C” for TNFR1 and the CD95-type DR CD95
(Continued)
FIGURE 6 | for statistical analysis. ***p < 0.001; **p < 0.01; n.s., not
significant. Please note (i) that cells do not, or only poorly, die [see lack/low
processing of effector caspase in (A) and PI staining in (B)] despite robust
caspase-8 activation/processing.
the overlapping occurrence of degradation and resynthesis of
IκBα resulting in a lack of correlation of accumulated active
nuclear NFκB transcription factors and net IκBα levels. Slow
but long-lasting activation of the classical NFκB pathway by
CD95-type DRs has also been observed previously [e.g., (22,
35)] and is in good accordance with the different localization
of TRADD, RIPK1, and TRAF2 in TNFR1-type and CD95-
type DR signaling. While TRADD, RIPK1, and TRAF2 recruit
within seconds to the TNFR1 signaling complex to engage
classical NFκB signaling (40), in the context of CD95-type DR
signaling, these molecules act in a secondary and delayed formed
DR-free cytosolic complex (1). The TRADD–RIPK1 dyad acts
upstream of TRAF2 in DR signaling and seems to be obligate
for DR-induced IL8 induction (5). TRAF2, however, seems to
be dispensable (Figures 4, 5). A possible explanation is that
the TRADD–RIPK1 dyad interacts with IKK-stimulating kinases
and the IKK complex itself in a TRAF2-independent manner.
Indeed, in this respect, there are several possibilities. First,
RIPK1 has the ability to directly interact with the NEMO/IKKγ
subunit of the IKK complex (41) and also binds the IKK-
stimulating kinase MEKK3, which furthermore interacts with
TAK1, another IKK-stimulating kinase (42, 43). Second, other
members of the TRAF family may substitute for TRAF2 in DR
signaling. In fact, a redundant role of TRAF2 and TRAF5 has
been reported in murine embryonal fibroblasts derived from
TRAF2–TRAF5 double-deficient mice (7). However, we were
unable to detect TRAF5 in our cell models and there is no
evidence yet in the literature for TRAF2–TRAF5 redundancy
in human cells. Since TRAF1 shares many interaction partners
with TRAF2, including RIPK1, TRADD, and NEMO/IKKγ
(27, 44), and furthermore forms heterotrimeric complexes with
TRAF2 (25), we looked for a role of TRAF1 in DR-induced
IL8 production. However, while reconstitution of TRAF2 in
HCT116-PI3Kmut-TRAF2KO cells restored IL8 induction by
death receptors, TRAF1 expression had no effect in these cells
(Figure 4). Refined biochemical analysis of DR-induced NFκB-
stimulating signaling complexes and generation and evaluation
of TRAF2–TRADD and TRAF2–RIPK1 double-deficient cells
may help in the future to get a clearer picture on the role
of TRAF2 in DR signaling.
CONCLUSION
TRAF2 significantly contributes to proinflammatory DR
signaling in a manner not replaceable by TRAF1 but has
definitely no obligate role in this respect. TRAF2 deficiency
enhances TNF-induced procaspase-8 processing but,
astonishingly, DR-induced net caspase-8 activity is reduced
due to reasons remain to be clarified.
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FIGURE 7 | The SMAC mimetic BV6 enhances TNF-induced procaspase-8 processing. (A) HCT116-PI3Kmut cells were pretreated or not with 10µM BV6 for 2 h
and were then stimulated with increasing concentrations of TNF for 10min. Phosphorylation and degradation of IκBα and cIAP1 expression were analyzed by Western
blotting. (B) HCT116-PI3Kmut (–) and HCT116-PI3Kmut-TRAF2KO (KO) cells were again pretreated with 10µM for 2 h and then stimulated overnight with 200 ng/ml
of TNF, TRAIL, or Fc-CD95L. IL8 production was determined by ELISA. Shown are results of three or four independent experiments. *p < 0.05; n.s., not significant.
(C) BV6-pretreated (2 h, 10µM) HCT116-PI3Kmut (–) and HCT116-PI3Kmut-TRAF2KO (TRAF2-KO) cells were stimulated with the indicated concentrations of TNF for
6 h in the presence of 2.5µg/ml CHX and subjected to Western blot analysis.
MATERIALS AND METHODS
Reagents and Cell Lines
Human Killer TRAIL (TRAIL) was purchased from Enzo Life
Sciences and TNF was a kind gift from Prof. Daniela Männel
(University of Regensburg). Fc-CD95L and TWEAK contain an
internal Flag tag and were produced by transient transfection of
HEK293 cells using PEI (Polysciences Inc., Warrington, USA)
as essentially described for other Flag-tagged proteins by Lang
et al. (45). Synthesis of BV6 has been described elsewhere
(46). Proteins were purified from the supernatant by affinity
chromatography on anti-Flag agarose (47). Cycloheximide
(CHX), MLN4924, and RPMI1640 were obtained from Sigma-
Aldrich (Deisenhofen, Germany), fetal calf serum was from
Gibco (Thermo Fisher Scientific, Darmstadt, Germany), z-
VAD-fmk was from Bachem (Heidelberg, Germany), and z-
IETD-fmk was from BD Biosciences (Heidelberg, Germany).
HCT116-PIK3CA-wt and HCT116-PIK3CA-mut were kindly
provided by B. Vogelstein (Johns Hopkins University, Baltimore,
USA). HT1080-Bcl2-TNFR2 cells were obtained by retroviral
transfection of HT1080-Bcl2(GFP) cells (described in 21) with
a mixture of a TNFR2 and a puromycin encoding vector.
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HCT116-PIK3CA-mut cells stably transfected with FLIPL and
FLIPS were generated as previously described for HaCaT
cells (36).
Molecular Cloning and Generation of
Stable Cell Lines
To generate TRAF2 KO cells, HCT116-PI3Kmut and HT1080-
Bcl2-TNFR2 cells were transfected as described below using
polyethylenimine (PEI, Polysciences Inc., Warrington, USA)
with a mixture of GeneArt CRISPR Nuclease (CD4 Reporter)
vector plasmids (ThermoFisher Scientific) encoding two TRAF2-
specific guide RNAs and Cas9. The TRAF2 guide sequences (5′ to
3′) used were as follows: CCTGAGCTGCCGGCATTGCGG and
GGACCTGGCGATGGCTGACTGG. The guide RNA sequences
were chosen from Table 1 of the supplementary website of
Mali et al. (48) (http://arep.med.harvard.edu/human_crispr/).
Transfected cells were cultivated for 5 days and then seeded at
low density to obtain individual clones. The latter was verified
for TRAF2 expression by WB to identify clones with successful
KO of TRAF2.
The sleeping beauty expression constructs were generated
as follows: A synthetic multi-cloning sequence containing sites
for NotI, MluI, NheI, SacII, NruI, SwaI, BglII, XbaI, and PacI
flanked by MfeI sites (CAATTGAGCG GCCGCACGCG
TGCTAGCCCG CGGGGAGGGT TTGTGGGTGA
GTCGCGAGAT TTAAATAGAT CTTCTAGAGT
TAATTAACAA TTG) were digested with MfeI and inserted into
the plasmid pT2-SVNeo EcoRI site [Addgene, plasmid described
in Cui et al. (49)], which is located between two inverted terminal
repeats of the sleeping beauty transposon resulting in the vector
pT2-SVNeo-MCS. DNA fragments encoding TRAF1 (NCBI
Ref. NM AK315476.1) and TRAF2 (NCBI Ref. NM_021138.3)
were initially inserted into the vector pTRE-Tight (Clontech,
cat. no. 631059) via BamHI and NotI (TRAF1) and BamHI
and XbaI (TRAF2) to generate pTRE-Tight-TRAF1 and pTRE-
Tight-TRAF2. The TRAF1 expression cassette (promoter, coding
region, SV40 polyA signal) of pTRE-Tight-TRAF1 was amplified
by PCR using primers flanked by SwaI and PacI and inserted
into the corresponding sites of pT2-SVNeo-MCS. In addition,
we inserted an amplicon containing the tetracycline-controlled
transactivator protein tTA-Advanced of the plasmid pTet-Off-
Advance (Clontech, cat. no. 630934) via the MluI and SwaI sites,
resulting in pT2-SVNeo-Tetoff-TRE-TRAF1. The corresponding
plasmid pT2-SVNeo-Tetoff-TRE-TRAF2 was obtained by
replacing the TRAF1 expression cassette with the corresponding
TRAF2 expression cassette of pTRE-Tight-TRAF2 via SwaI and
PacI. The TRAF1 and TRAF2 encoding pT2-SVNeo plasmids
were then used with pCMV-(CAT)T7-SB100 [Addgene, plasmid
described in Cui et al. (49)] encoding the sleeping beauty
transposon and pT2-SVPuro-CMV-TST206 (kind gift of
Thorsten Stühmer, University Hospital Würzburg) encoding
a puromycin resistance gene flanked by the sleeping beauty
inverted terminal repeats to generate stable TRAF1 and TRAF2
transfectants. For this, cells were transfected chemically using
PEI. In brief, 36 µl of a 1 mg/ml solution PEI was mixed with 12
µg of expression vector [60% pT2-SVNeo-Tetoff-TRE-TRAF1 or
pT2-SVNeo-Tetoff-TRE-TRAF2, 30% pCMV-(CAT)T7-SB100,
pT2-SVPuro-CMV-TST206] and incubated for 15min at room
temperature. The mixture was added to the cells with 15ml of
RPMI1640, and the next day, mediumwas changed with medium
containing 10% FCS and 1µg/ml puromycin for selection. After
7–10 days, single cells were seeded, expanded, and checked for
TRAF1 and TRAF2 expression.
Viability Assay
Cells (4 × 104 cells/96-well) were challenged with Killer-
TRAIL (TRAIL) in triplicate. The next day, cell viability
was determined using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide) staining. The optical density
(OD) was measured by PHOMO (Anthos), and the values
obtained were normalized according to the values of cells
receiving no TRAIL (= 100% viability) and cells that have
been treated with a cytotoxic mixture containing 200 ng/ml
TNF, 200 ng/ml Fc-CD95L, 200 ng/ml TWEAK, 5µg/ml CHX,
1µg/ml puromycin, and 0.02% sodium azide (= 0% viability).
Microscopy
For light microscopy analysis, cells were seeded in 96-well plates
and stimulated as described before. Pictures were taken randomly
using an Evos X1 microscope.
ELISA
HCT116-derived cell variants we re seeded with 4 × 104
cells/well, and the HT1080-derived cell variants were seeded with
2× 104 cells/well. The next day, cell culturemediumwas replaced
to minimize the background caused by constitutive cytokine
production before cells were stimulated with the cytokine of
interest. After an additional day, cleared supernatants were
evaluated for their IL8 content using an IL8 enzyme-linked
immunosorbent assay (ELISA) kit (BD Biosciences, Heidelberg,
Germany) according to the manufacturer’s protocol.
Western Blot
Cells (2 × 106 per 6-well) were stimulated as indicated in
the various figure legends and were scratched on ice. After
two washes with ice-cold PBS, total cell lysates were generated
by dissolving cells for 5min at 95◦C in Laemmli buffer
and sonification (UP100H, Helscher, cycle 1, 100% amplitude,
52 s). Total cell lysates were separated by SDS-PAGE and
proteins were transferred to 0.2-µm nitrocellulose blotting
membranes (GE Healthcare Life Sciences). Membranes were
blocked with 5% non-fat-dried milk in TBS-Tween [0.05%
(v/v)], and the proteins of interest were detected with the
corresponding primary antibodies (4◦C, overnight, TBST) and
HRP-linked secondary antibodies (RT, 1–3 h, 2.5% nonfat-
dried milk). Antibody complexes were visualized with the ECL
solution. Between every step, membranes were washed three
times with TBS-Tween [0.05% (v/v)]. The following antibodies
were used: anti-caspase-3 (8G10), anti-caspase-9 (#9502), anti-
DR4 (D9S1R), anti-DR5 (D4E9), anti-FADD (#2782), anti-
phospho-IκBα (Ser32) (14D4), anti-IκBα (L35A5), anti-alpha-
Fodrin (#2122), anti-CYLD (D1A10), anti-TRAF1 (45D3), anti-
TRAF2 (C192), anti-A20 (D13H3), anti-mouse IgG, HRP-linked
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antibody (#7076), anti-rat IgG, HRP-linked antibody (#7077) and
anti-rabbit IgG, HRP-linked antibody (#7074), which were all
from Cell Signaling. Furthermore, anti-PARP (BD Biosciences),
HRP-conjugated polyclonal rabbit anti-mouse immunoglobulins
(P0260, Dako), anti-caspase-8 (5F7, Enzo), anti-cIAP1 (1E1-1-
10, Enzo), anti-tubulin (DM1A, Thermo Fisher Scientific), anti-
β-actin (A1978-200 µl, Sigma Aldrich), anti-TRAF1 (H-132; sc-
1831; Santa Cruz), anti-FLIP (NF6, AdipoGen), and anti-p52
(05-361, Millipore) have been used.
Caspase-8 Activity Assay
Cells were cultivated in 12-well plates until they reached a
density of approximately 3 × 106 cells per well. Cells were
stimulated for 6 h with the indicated reagents and were
harvested after a 5-min incubation with trypsin according to
the manufacturer’s protocol [Application note No. 3021. Rev.
1.3 of NucleoCounter R© NC-3000TM (Chemometec)]. Cells
were stained using the FAM-FLICA R© Caspase-8 Assay Kit
(Immunochemistry Technologies; Catalog no. 910). Stained
cells were analyzed using NucleoCounter R© NC-3000TM
software and the values were diagrammed by Graph Pad
Prism 5 software.
Statistical Analysis
Measurements of independent experiments were collected and
analyzed using the one-way ANOVA Bonferroni’s multiple
comparison test function of the GraphPad Prism5 software
(GraphPad software, La Jolla, CA, USA).
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